Can Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY)’s Tomorrow Be Different? The Stock Had Decline in Shorts

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Logo

The stock of Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY) registered a decrease of 19.69% in short interest. NBY’s total short interest was 31,400 shares in March as published by FINRA. Its down 19.69% from 39,100 shares, reported previously. With 7,700 shares average volume, it will take short sellers 4 days to cover their NBY’s short positions. The short interest to Novabay Pharmaceuticals Inc’s float is 0.46%.

The stock decreased 0.62% or $0.0088 during the last trading session, reaching $1.4219. About 400 shares traded. NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has declined 59.94% since March 17, 2018 and is downtrending. It has underperformed by 64.31% the S&P500.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $24.30 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

Another recent and important NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) news was published by which published an article titled: “Myomo Makes NYSE American Section 610(b) Public Announcement – Business Wire” on March 15, 2019.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.